Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML.

Shayegi N, Kramer M, Bornhäuser M, Schaich M, Schetelig J, Platzbecker U, Röllig C, Heiderich C, Landt O, Ehninger G, Thiede C; Study Alliance Leukemia (SAL).

Blood. 2013 Jul 4;122(1):83-92. doi: 10.1182/blood-2012-10-461749. Epub 2013 May 8.

2.

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B; German High-Grade Lymphoma Study Group (DSHNHL).

Lancet Oncol. 2012 Dec;13(12):1250-9. doi: 10.1016/S1470-2045(12)70481-3. Epub 2012 Nov 16.

PMID:
23168367
3.

SOCS1 cooperates with FLT3-ITD in the development of myeloproliferative disease by promoting the escape from external cytokine control.

Reddy PN, Sargin B, Choudhary C, Stein S, Grez M, Müller-Tidow C, Berdel WE, Serve H, Brandts CH; Study Alliance Leukemia (SAL).

Blood. 2012 Aug 23;120(8):1691-702. Epub 2012 Apr 19.

4.

Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators.

N Engl J Med. 2012 Feb 16;366(7):601-9. doi: 10.1056/NEJMoa1108898.

5.

Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation.

Michallet M, Dreger P, Sutton L, Brand R, Richards S, van Os M, Sobh M, Choquet S, Corront B, Dearden C, Gratwohl A, Herr W, Catovsky D, Hallek M, de Witte T, Niederwieser D, Leporrier M, Milligan D; EBMT Chronic Leukemia Working Party.

Blood. 2011 Feb 3;117(5):1516-21. doi: 10.1182/blood-2010-09-308775. Epub 2010 Nov 24.

6.

Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia.

Müller-Tidow C, Klein HU, Hascher A, Isken F, Tickenbrock L, Thoennissen N, Agrawal-Singh S, Tschanter P, Disselhoff C, Wang Y, Becker A, Thiede C, Ehninger G, zur Stadt U, Koschmieder S, Seidl M, Müller FU, Schmitz W, Schlenke P, McClelland M, Berdel WE, Dugas M, Serve H; Study Alliance Leukemia.

Blood. 2010 Nov 4;116(18):3564-71. doi: 10.1182/blood-2009-09-240978. Epub 2010 May 24.

7.

High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG.

Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S, Ludwig WD, Staib P, Aul C, Grüneisen A, Kern W, Reichle A, Serve H, Berdel WE, Braess J, Spiekermann K, Wörmann B, Sauerland MC, Heinecke A, Hiddemann W, Hehlmann R, Büchner T; German AML Cooperative Group.

Leukemia. 2009 Dec;23(12):2248-58. doi: 10.1038/leu.2009.183. Epub 2009 Sep 10.

PMID:
19741727
8.

E3 ligase-defective Cbl mutants lead to a generalized mastocytosis and myeloproliferative disease.

Bandi SR, Brandts C, Rensinghoff M, Grundler R, Tickenbrock L, Köhler G, Duyster J, Berdel WE, Müller-Tidow C, Serve H, Sargin B; Study Alliance Leukemias.

Blood. 2009 Nov 5;114(19):4197-208. doi: 10.1182/blood-2008-12-190934. Epub 2009 Sep 4.

9.

Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice.

Zeis M, Uharek L, Glass B, Gaska T, Steinmann J, Gassmann W, Löffler H, Müller-Ruchholtz W.

Transplantation. 1995 Jun 27;59(12):1734-6. No abstract available.

PMID:
7604444
10.

Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.

Zeis M, Uharek L, Glass B, Gaska T, Gassmann W, Mueller-Ruchholtz W.

Bone Marrow Transplant. 1994 Nov;14(5):711-5.

PMID:
7889004
11.

Influence of donor lymphocytes on the incidence of primary graft failure after allogeneic bone marrow transplantation in a murine model.

Uharek L, Glass B, Gaska T, Gassmann W, Loeffler H, Mueller-Ruchholtz W.

Br J Haematol. 1994 Sep;88(1):79-87.

PMID:
7803260
12.

Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.

Uharek L, Glass B, Gaska T, Zeiss M, Gassmann W, Löffler H, Müller-Ruchholtz W.

Bone Marrow Transplant. 1993;12 Suppl 3:S57-60.

PMID:
8124260
13.

The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment.

Glass B, Uharek L, Gaska T, Gassmann W, Löffler H, Müller-Ruchholtz W.

Bone Marrow Transplant. 1993;12 Suppl 3:S41-7.

PMID:
8124257

Supplemental Content

Loading ...
Support Center